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Background: With the combined treatment procedure of isolated limb perfusion (ILP),
delayed surgical resection and external beam radiotherapy (EBRT) for locally advanced soft
tissue sarcomas (STS) of the extremities, limb salvage rates of more than 80% can be achieved.
However, long-term damage to the healthy surrounding tissue cannot be prevented. We
studied the late effects on the normal tissue using the LENT-SOMA scoring system.
Patients and Methods: A total of 32 patients—median age 47 (range 14–71) years—were
treated for a locally advanced STS with ILP, surgical resection and often adjuvant 60–70 Gy
EBRT. After a median follow-up of 88 (range 17–159) months, the patients were scored, using
the LENT-SOMA scales, for the following late tissue damage: muscle/soft tissue, peripheral
nerves, skin/subcutaneous tissue and vessels.
Results: According to the individual SOM parameters of the LENT-SOMA scales, 20 pa-
tients (63%) scored grade-3 toxicity on one or more separate items, reﬂecting severe symptoms
with a negative impact on daily activities. Of these patients, 3 (9%) even scored grade-4
toxicity on some of the parameters, denoting irreversible functional damage necessitating
major therapeutic intervention.
Conclusions: In evaluating long-term morbidity after a combined treatment procedure for
STS of the extremity, using modiﬁed LENT-SOMA scores, two-thirds of patients were found
to have experienced serious late toxic effects.
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In the 1960s and 1970s, the eﬀectiveness of
(neo)adjuvant isolated limb perfusion (ILP) with
various cytostatics was explored in the limb salvage
treatment of extremity sarcomas.
1 The practice of
performing extremity perfusions for sarcomas ended
after Rosenberg showed the effectiveness of adjuvant
radiation treatment in limb salvage. Amputations or
exarticulations of the affected limb did not result in
higher survival rates.
2,3
There was a renewed interest in neoadjuvant ILP in
the early 1990s, when Lejeune and co-workers added
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1502tumor necrosis factor alpha (TNFa) to Melphalan in
the ILP treatment of locally advanced extremity
melanomas and sarcomas. This resulted in high local
response rates and high limb salvage rates with an
acceptable local and systemic toxicity.
4,5
Currently, an established limb salvage strategy for
primarilyirresectablesofttissuesarcomas(STSs)ofthe
limbsconsistsofinductiontreatmentwithhyperthermic
ILP with TNFa and Melphalan, followed by delayed
surgical resection and, in case of marginal or non-rad-
ical resection, adjuvant external beam radiotherapy
(EBRT). With this combined treatment modality,
short-term limb salvage rates of more than 80% are
achieved, with long-term rates of 60%.
5,6 However, as
thenumberoflong-termcancersurvivorsincreases,late
complications of therapy will become an increasingly
important concern.
7 Long-term damage to the healthy
surroundingtissuecannotbeprevented.Toxiceffectsof
pre- or postoperative EBRT and intra-arterial chemo-
therapy have been extensively described in previous
literature and include edema, ﬁbrosis, neuropathy,
limited mobility, impaired wound healing and, less
commonly, pain, bone fractures and second
tumors.
3,8–11 Moreover, during ILP, normal tissue in
the limb—skin, subcutaneous tissue, muscle, nerves,
blood vessels, bone and cartilage—is exposed to the
same concentrations of cytostatic agents active against
the tumor, causing regional toxic effects, which lead to
comparable late complications.
12 Recently, we de-
scribed the late vascular complications that occur after
the TNF ILP treatment procedure.
13 Functional mor-
bidity and symptoms such as edema and pain can also
be extremely invalidating, sometimes necessitating
aggressive treatment. To evaluate all toxic long-term
effects,weusedtheuniform,generallyacceptedtoxicity
scoring system ‘‘LENT-SOMA’’. This system not only
allows late damage to be classiﬁed in different grada-
tions, but also allows data acquisition using three dif-
ferent methods: (1) subjective, the injury is recorded as
perceived by the patient; (2) objective, morbidity is as-
sessed during a clinical examination; and (3) manage-
ment, indicates the active steps made to ameliorate the
symptoms.
14 In order to provide an overview of all late
toxic effects on the limb treated with ILP, delayed sur-
gical resection and adjuvant high-dose EBRT, a retro-
spective study was conducted to evaluate long-term
morbidity using the LENT-SOMA scoring system.
PATIENTS AND METHODS
Between 1991 and 2003, 73 patients with locally
advanced STSs underwent 77 perfusions with a
combination of TNFa and Melphalan, with (n = 19)
or without (n = 58) interferon-gamma (IFNc), at the
Division of Surgical Oncology of the University
Medical Center Groningen (UMCG). The perfusion
technique has been previously described exten-
sively.
15,16 Currently, 39 patients are still alive and in
follow-up. There were 7 patients who were unable to
participate because of severe or advanced (co-)mor-
bidity (n = 2) or non-medical reasons (n = 5).
Consequently, 32 patients, 14 males (44%) and 18
females (56%), median age 47 (range 14–71) years,
could be evaluated (response rate 82%). Of all the 32
patients, 5 had STSs of the upper extremity (16%),
treated with an axillary perfusion. In the remaining
27, they were located in the lower limb (84%) and
were treated with iliacal (n = 13, 41%), femoral
(n = 5, 16%) or popliteal (n = 9, 28%) perfusion.
There were 27 primary (84%) and 5 recurrent (16%)
STSs.
After a median post-perfusion duration of 8 (range
6–12) weeks, all patients underwent a delayed local
resection of the tumor remnant. Of the patients, 25
had clear microscopic surgical margins (R0 resection,
78%) and 7 had histologically positive microscopic
margins (R1 resection, 22%). No patient had mac-
roscopic residual disease. A total of 24 patients (75%)
with marginal (£1 cm, n = 17) or microscopically
positive resection (n = 7) margins received adjuvant
high dose (60–70 Gy) postoperative EBRT in 25
fractions of 2 Gy, followed by a boost of 10–20 Gy.
One patient with a recurrent STS received EBRT at
the time of treatment of the primary tumor, but not
after ILP and resection of the recurrence. Adjuvant
systemic chemotherapy was given to 7 patients: 2 due
to the definite histopathological classification of the
tumor (one embryonal rhabdomyosarcoma and one
extraosseal osteosarcoma); 3 as part of an EORTC
trial (EORTC 62931);
17 and 2 in a palliative setting
because of distant metastasis.
All patients received a tailored post-surgical reha-
bilitation program, during and after the radiation
treatment, until a ﬁnal result was achieved. All
patients were treated after informed consent was
obtained according to institutional guidelines. A total
of 12 diﬀerent histological types of STS were distin-
guished. The pathological grade and stage of the
tumor were scored according to the criteria of
Coindre et al. and the American Joint Committee on
Cancer (AJCC), respectively.
18,19 Patient and tumor
characteristics are summarized in Table 1.
Local status of the treated limb was ﬁrst globally
assessed using a checklist including the following
items: lymphedema, color, stiﬀness, hypesthesia,
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tion and use of aids.
Late eﬀects on surrounding tissue were graded
according to the subjective, objective and manage-
ment portions of the LENT-SOMA scales, as pro-
posed by the EORTC and RTOG Late Eﬀects
Working Group in 1995.
14,20,21 Four LENT-SOMA
scales were used: muscle/soft tissue, peripheral
nerves, skin/subcutaneous tissue and vessels.
22 Not
all patients could be scored on all four items, since in
5 patients (16 %) the affected limb was amputated.
RESULTS
After a median follow-up of 88 (range 17–159)
months, 14 patients (44%) mentioned one or more
locoregional complaints in the treated leg, mainly
consisting of pain, spasm and limitation of mobility.
Scoring the local status using a checklist, deviating
symptoms and signs were documented and are sum-
marized in Table 2. Only 15 patients (47%) did not
use any aids; the remaining 17 (53%) needed elastic
compression stockings, braces, prostheses or crutches.
LENT-SOMA Scales
Results of scoring late tissue eﬀects according to
the LENT-SOMA scoring system are listed below
and illustrated in Table 3. Grade 1 represents the
most minor symptoms, which do not require treat-
ment. Grade 2 represents moderate symptoms,
requiring only conservative treatment. Grade 3 rep-
resents severe symptoms, which have a signiﬁcant
negative impact on daily activities and require more
aggressive treatment. Grade 4 represents irreversible
TABLE 1. Characteristics of patients. PNET primitive neuroectodermal tumor, PUS pleiomorphic undifferentiated sarcoma,
MPNST malignant peripheral nerve sheath tumor, FU follow-up in months, na not available
Age (years) Sex Histology Grade AJCC stage Level EBRT Amputation FU
18 Female Primary Embryonal rhabdomyosarcoma 3 3 Iliacal No No 159
44 Female Recurrent Myxoid liposarcoma 1 1 Iliacal Yes No 152
43 Male Primary Synovial sarcoma 3 3 Iliacal Yes No 151
18 Male Primary Myxoid chondrosarcoma 2 3 Popliteal Yes Yes 149
48 Female Primary Well-differentiated liposarcoma 1 1 Iliacal Yes No 143
56 Female Primary PNET 3 3 Iliacal Yes Yes 137
50 Female Recurrent PUS 3 3 Popliteal No No 135
25 Female Primary Synovial sarcoma 2 3 Popliteal Yes No 132
44 Male Primary Myxoid liposarcoma 1 1 Iliacal Yes No 131
24 Male Recurrent Synovial sarcoma 2 3 Popliteal Yes No 129
37 Female Primary MPNST 2 3 Axillary Yes No 121
48 Male Primary Myxoid liposarcoma 2 3 Iliacal Yes No 111
63 Female Recurrent PUS 2 3 Popliteal No Yes 107
37 Male Primary Myxoid liposarcoma 1 1 Iliacal Yes No 105
58 Male Primary PUS 2 3 Iliacal Yes No 98
71 Female Primary Leiomyosarcoma 1 1 Femoral No No 94
45 Female Primary PUS 3 3 Iliacal No No 82
56 Female Primary PUS 3 3 Popliteal Yes No 61
63 Male Primary Myxoid chondrosarcoma na 3 Femoral Yes No 50
37 Female Primary Leiomyosarcoma 1 1 Femoral Yes No 36
28 Male Primary Synovial sarcoma 2 3 Femoral Yes No 36
57 Female Primary PUS 3 3 Femoral Yes No 35
42 Female Primary Synovial sarcoma 2 3 Iliacal Yes Yes 32
47 Female Primary PUS 3 3 Axillary Yes No 30
58 Female Primary PUS 3 3 Popliteal Yes No 26
27 Male Primary Epithelioid sarcoma 3 4 Axillary Yes No 26
71 Male Recurrent Myxoid ﬁbrosarcoma 1 1 Axillary No No 24
56 Female Primary PUS 3 3 Axillary No No 22
14 Male Primary PUS 3 3 Popliteal Yes No 20
65 Female Primary Synovial sarcoma 2 3 Popliteal No Yes 18
63 Male Primary Synovial sarcoma 3 3 Iliacal Yes No 17
71 Male Primary Rhabdomyosarcoma 3 3 Iliacal Yes No 17
TABLE 2. Local status in 32 patients: deviating symptoms
and signs
Symptom No. %
Lymphedema 14 44
Discoloration 18 56
Stiffness 16 50
Atrophy 27 84
Pain 5 16
Hypesthesia 17 53
Paresthesia 13 41
Function
- Limited 18 56
- Severely limited 4 13
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intervention. SOMA stands for: S, subjective com-
plaints; O, objective symptoms; and M, management
and therapy.
Muscle/Soft Tissue
Of the patients, 6 experienced no subjective toxic
eﬀects (19%), 9 scored maximum grade 1 (29%), 2
scoredgrade2(6%)and14hadamaximumofgrade-3
toxicity (45%). When scored objectively, a maximum
of grade-2 toxicity was found in 15 patients (48%) and
grade 3 in 16 patients (52%). No patient had only
minor or no symptoms. No treatment was required in
20 patients (65%), 1 patient (3%) scored grade 1
(occasional physiotherapy), 9 scored grade 2 (29%)
and 1 (3%) needed continued medical intervention
(grade 3) for edema and extremity malfunction. A
detailed overview of all items is provided in Table 4.
Peripheral Nerves
No subjective toxic eﬀects were observed in 6
patients (20%), 3 scored maximum grade-1 toxicity
(10%), 9 scored grade 2 (30%) and 12 grade-3
toxicity (40%). When scored objectively, 6 patients
experienced no toxicity (21%), and 12 scored grade-1
(43%), 7 grade-2 (25%) and 3 grade-3 (11%) toxic
eﬀects. Of the patients, 23 did not require any treat-
ment (77%), 1 (3%) scored grade-1 (occasional non-
narcotic), 4 (13%) grade-2 (regular non- narcotic)
and 2 (7%) grade-3 (physical or medical intervention
because of severe motor dysfunction) toxicity. A
detailed overview is provided in Table 5.
TABLE 3. Modiﬁed LENT-SOMA scores
Maximum grade of toxicity
0123 4
Muscle/ soft tissue (n = 31)
Subjective 6 19% 9 29% 2 6% 14 45% 0 0%
Objective 0 0% 0 0% 15 48% 16 52% 0 0%
Management 20 65% 1 3% 9 29% 1 3% 0 0%
Peripheral nerves (n = 30)
Subjective 6 20% 3 10% 9 30% 12 40% 0 0%
Objective
a 6 21% 12 43% 7 25% 3 11% 0 0%
Management 23 77% 1 3% 4 13% 2 7% 0 0%
Skin/subcutaneous tissue (n = 27)
Subjective 8 30% 15 56% 2 7% 2 7% 0 0%
Objective 1 4% 6 22% 15 56% 5 19% 0 0%
Management 23 85% 0 0% 0 0% 2 7% 2 7%
Vessels (n = 25)
Subjective 16 64% 4 16% 4 16% 1 4% 0 0%
Objective 13 52% 8 32% 2 8% 1 4% 1 4%
Management 18 72% 4 16% 0 0% 1 4% 2 8%
a n = 28.
TABLE 4. LENT-SOMA scores for muscle/soft tissue (n = 31)
Grade of toxicity
0123 4 N A
Subjective
- Pain 20 65% 7 23% 2 6% 2 6% 0 0% 0 0%
- Function 6 19% 9 29% 2 6% 14 45% 0 0% 0 0%
Objective
- Edema 14 45% 10 32% 4 13% 2 6% 0 0% 1 3%
- Mobility and extremity function 6 19% 9 29% 11 35% 5 16% 0 0% 0 0%
- Fibrosis 1 3% 3 10% 15 48% 10 32% 0 0% 0 0%
- Atrophy 0 0% 3 10% 16 52% 10 32% 0 0% 2 6%
- Contraction 18 58% 0 0% 12 39% 0 0% 0 0% 1 3%
Management
- Pain 25 81% 3 10% 3 10% 0 0% 0 0% 0 0%
- Edema 24 77% 0 0% 5 16% 1 3% 0 0% 1 3%
- Mobility and extremity function 27 87% 1 3% 2 6% 1 3% 0 0% 0 0%
- Fibrosis 29 94% 1 3% 0 0% 0 0% 0 0% 1 3%
- Atrophy 29 94% 0 0% 1 3% 0 0% 0 0% 1 3%
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No subjective symptoms were observed in 8patients
(30%), 15 scored maximum grade-1 toxicity (56%), 2
grade 2 (7%) and 2 (7%) grade 3 (scaliness/roughness
requiring constant attention). Only 1 patient experi-
encednoobjectivetoxicity(4%),while6scoredgrade1
(22%), 15 grade 2 (56%) and 5 grade 3 (19%). No
treatment was required in 23 patients (85%), but 2
(7%) required medical intervention because of edema
and dryness (grade-3 toxicity) and 2 (7%) scored
grade-4 toxicity—surgical intervention due to massive
ﬁbrosis and a persistent ulcer requiring surgical ther-
apy. A detailed overview is provided in Table 6.
Vessels
No subjective symptoms were observed in 16 pa-
tients (64%), while 4 scored maximum grade-1 (16%),
4 grade-2 (16%) and 1 grade-3 (4%) toxicity: clinical
symptoms of ischemia at rest. Objective symptoms
were absent in 13 patients (52%), but 8 patients scored
grade-1 toxicity (32%), 2 scored grade 2 (8%), 1 grade
3 (intense ischemia) (4%) and 1 grade 4 (necrosis)
(4%). No form of management was needed in 18 pa-
tients (72%). However, 4 patients scored grade 1
(16%), 1 (4%) grade 3 (conservative surgery because
of arterial disease) and 2 (8%) required amputation
(grade-4 toxicity) because of critical leg ischemia. A
detailed overview is provided in Table 7.
Overall,outcomesfromtheSubjectiveandObjective
symptoms are different from those of the Management
part of the LENT-SOMA scales. According to the
subjectiveandobjectivepartsofthescale,two-thirdsof
patients had serious late toxic side effects concerning
any of the surrounding normal tissue. A grade-3
TABLE 5. LENT-SOMA scores for peripheral nerves (n = 30)
Grade of toxicity
012 3 4 N A
Subjective
- Pain 20 67% 7 23% 1 3% 2 7% 0 0% 0 0%
- Strength 7 23% 1 3% 12 40% 8 27% 0 0% 2 7%
- Sensory 10 33% 11 37% 2 7% 6 20% 0 0% 1 3%
- Motor paresis 14 47% 8 27% 5 17% 2 7% 0 0% 1 3%
Objective
- Motor dysfunction 7 23% 11 37% 7 23% 2 7% 1 3% 2 7%
- Sensory dysfunction 12 40% 12 40% 3 10% 1 3% 0 0% 2 7%
- Reﬂex 17 57% 7 23% 3 10% 0 0% 0 0% 3 10%
Management
- Pain 22 73% 3 10% 4 13% 0 0% 0 0% 1 3%
- Motor dysfunction 25 83% 0 0% 0 0% 2 7% 0 0% 3 10%
- Sensory dysfunction 27 90% 0 0% 0 0% 0 0% 0 0% 3 10%
- Sensory 27 90% 0 0% 0 0% 0 0% 0 0% 3 10%
TABLE 6. LENT-SOMA scores for skin/subcutaneous tissue (n = 27)
Grade of toxicity
012 3 4 N A
Subjective
- Scaliness/ roughness 9 33% 16 59% 0 0% 2 7% 0 0% 0 0%
- Sensation 20 74% 5 19% 2 7% 0 0% 0 0% 0 0%
Objective
- Edema 11 41% 8 30% 5 19% 2 7% 0 0% 1 4%
- Alopecia (scalp) 9 33% 13 48% 3 11% 1 4% 0 0% 1 4%
- Pigmentation change 6 22% 8 30% 11 41% 1 4% 0 0% 1 4%
- Ulcer/ necrosis 25 93% 1 4% 1 4% 0 0% 0 0% 0 0%
- Teleangiectasia 16 59% 7 26% 3 11% 0 0% 0 0% 1 4%
- Fibrosis/ scar 2 7% 19 70% 6 22% 0 0% 0 0% 0 0%
- Atrophy/ contraction 2 7% 15 56% 6 22% 2 7% 0 0% 2 7%
Management
- Dryness 23 85% 1 4% 1 4% 1 4% 0 0% 1 4%
- Sensation 26 96% 0 0% 0 0% 0 0% 0 0% 1 4%
- Ulcer 26 96% 0 0% 0 0% 0 0% 1 4% 0 0%
- Edema 25 93% 0 0% 0 0% 2 7% 0 0% 0 0%
- Fibrosis/ scar 26 96% 0 0% 0 0% 0 0% 1 4% 0 0%
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more items of the subjective parts of the four used
scales. They experienced their long-term morbidity as
severe and with a negative impact on daily activities.
Grade-3or -4 toxicity was scored by 18 patients (56%)
on the objective parts of the scoring scales, showing
severe or irreversible damage during a clinical exami-
nation. However, according to the management parts,
16 patients (50%) scored no toxicity (grade 0) on all
management items of the four used LENT-SOMA
scales and did not require any treatment. Moreover, 9
patients (28%) scored a maximum grade-1 or -2 tox-
icity and only needed conservative treatment. In less
than a quarter of patients (n = 7, 22%), aggressive
treatment, e.g., continuous medical intervention or
surgery, was necessary due to long-term effects of the
combined treatment procedure.
DISCUSSION
The limb-sparing treatment strategy of ILP using
TNF and Melphalan—with or without adjuvant
EBRT—is increasingly being pursued for locally ad-
vanced STS of the extremities after the publication of
the results of a European multi-center trial performed
in the 1990s. Using this combined treatment modal-
ity, excellent short-term limb salvage rates of more
than 80% and long-term rates of 60% can be
achieved with no negative impact on survival.
5,6
While, at ﬁrst, selected groups of patients were often
excluded from undergoing this procedure, limb
preservation has now become a major challenge for
all patients with a locally advanced STS.
Itseemstobeasafeandhighlyeﬀectiveprocedurein
elderly patients, for whom every attempt to avoid an
amputation that may end their independence must be
considered.
23 It can also be used in a palliative setting
for patients who present with distant metastasis at the
time of diagnosis, as better local control improves the
quality of life.
24 In patients with multifocal primary or
multiple recurrent extremity sarcomas, ILP also pro-
vides excellent local control and limb salvage rates of
more than 80% are achieved.
25
However, acute toxicity and long-term morbidity
due to the combined treatment procedure of ILP,
surgical resection and EBRT cannot be prevented. In
ILP, normal tissue in the limb is exposed to the same
concentrations of cytostatic agents as the tumor. The
eﬀects of the perfusate on normal tissue vary widely
among individuals and long-term morbidity also
varies widely in severity.
As far as we know, this is the ﬁrst study to assess
late functional morbidity with the LENT-SOMA
scales in patients treated for STS with ILP, surgical
resection and EBRT.
Neurotoxicity
Neuropathy is particularly important and is mainly
seen after the use of speciﬁc cytostatic perfusion
agents, such as cisplatin, carboplatin and doxorubi-
cin.
26–28 Furthermore, nerve damage can be caused
by initial tumor swelling or pressure from the tight
tourniquet.
29,30 A prophylactic fasciotomy can pre-
vent the occurrence of a persistent neurotoxicity with
motor-sensory neuropathy and is routinely per-
formed in our series.
31 Radiotherapy also plays an
important role, especially when patients have received
a boost.
32 All our patients received a boost of
10– 20 Gy EBRT. Despite the fact that neurotoxicity
was subjectively found to be severe in 40% of
patients, only in 11% could it be objectified, and in
only 7% was physical or medical intervention needed.
None of the patients had paralysis or complete
anesthesia or needed surgical intervention.
Functional Morbidity
Functional outcome after limb-sparing treatment
with ILP has been analyzed previously, but mostly in
TABLE 7. LENT-SOMA scores for vessels (n = 25)
Grade of toxicity
01 2 3 4 N A
Subjective
- Arterial 20 80% 1 4% 3 12% 1 4% 0 0% 0 0%
- Venous 20 80% 4 16% 1 4% 0 0% 0 0% 0 0%
Objective
- Arterial 22 88% 0 0% 1 4% 1 4% 1 4% 0 0%
- Venous 16 64% 8 32% 1 4% 0 0% 0 0% 0 0%
Management
- Arterial 22 88% 0 0% 0 0% 1 4% 2 8% 0 0%
- Venous 21 84% 4 16% 0 0% 0 0% 0 0% 0 0%
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system. Other studies show limitations in ankle joint
mobility in 25–40% of patients, compared with no
significant objective limitations in previous investiga-
tions in our study population.
12,33 The routinely per-
formed fasciotomy, combined with an intensive
physiotherapy program, might explain these better
outcomes because the regional toxic effects of ILP are
hereby reduced.
34 In this study, we found muscle
atrophyinalmostallpatients(96%),whichmaybedue
to an extensive surgical resection having been per-
formed after ILP for deep-seated STSs, in contrast to
the mostly superﬁcial resection in melanoma patients.
Only 4 patients (13%) still needed medical interven-
tion: occasional or regular physiotherapy. However,
14 patients (44%) found that their limb function
interferedwithdailyactivities.Inonly6patients(19%)
could no functional impairment be objectiﬁed.
Scoring Systems
Most previous studies evaluating functional out-
come after treatment for STS included no ILP, but
consisted of wide local excision with or without
postoperative EBRT and/or adjuvant chemotherapy.
Gerrand et al. found a signiﬁcant decrease in func-
tional scores when the revised Musculoskeletal Tumor
Society Rating Scale (MSTS) and Toronto Extremity
Salvage Score (TESS) were used after treatment of
deep-seated tumors
35. In two studies, the LENT-
SOMA scales were used to assess functional morbid-
ity after wide local excision and EBRT sometimes
combined with chemotherapy for STS. The LENT-
SOMA scales were found to be time-consuming, but
reliable for a detailed description of late toxicity.
32,36
To evaluate the long-term morbidity in our study,
we used this generally accepted LENT-SOMA scor-
ing system. According to Denekamp et al., no overall
LENT score is calculated but all criteria are sepa-
rately described in order to prevent the high scores
being ﬁltered out, thus giving a falsely optimistic
picture.
37 Although primarily developed to analyze
late radiation effects, it can also be used to score the
toxicity of chemotherapy.
21 In this study, 25 of the 32
patients analyzed (78%) received EBRT. The 3 pa-
tients who scored grade-4 toxicity on one or more
items all received EBRT. Overall, there was no
patient who did not experience any late toxic effect.
Quality of Life
All functional complaints can have a substantial
negative impact on daily functioning, which brings
into question whether expectations of the time-con-
suming technically demanding limb-sparing treat-
ment are upheld. Previous studies showed no
improved quality of life with limb-sparing surgery
compared with that after amputation.
38,39 The long
rehabilitation period is a disadvantage of a limb-
sparing treatment strategy, but the impact of a
prosthesis should not be underestimated. Thijssens
et al. recently showed a worse physical functioning
and more role limitations in amputated patients in
this study population. Attention to collaborative
decision making and communication with the patient
seem very important.
40
Future Perspectives
Every eﬀort should be made to prevent long-term
morbidity in the future. As long-term morbidity seems
to be correlated to acute regional toxic reactions, these
acute reactions should be reduced as far as possible.
30
Improved perfusion technique and enhanced technical
insights have led to the following suggestions: reduce
the doses of TNFa, decrease systemic leakage, reduce
maximum temperatures and strictly regulate perfu-
sion pressures.
15,30,41 To prevent the signiﬁcant tox-
icity related to muscle and nerve damage, a
prophylactic fasciotomy should be performed in all
cases and the isolating tourniquet should not be ap-
plied too tightly.
30,31 Furthermore, all patients should
receive an individualized rehabilitation program to
achieve an optimum functional situation.
Finally, a lot of long-term morbidity after EBRT is
subscribed to the occurrence of radiation-induced
ﬁbrosis, which was thought to be irreversible.
7 Thanks
to the pioneering work of Delanian et al., there is
growing knowledge that radiation-induced ﬁbrosis is
at least partially reversible by administering drugs
with antioxidant and anti-ﬁbrotic properties, such as
pentoxifylline and vitamin E. Large randomized trials
are, however, needed to conﬁrm these ﬁndings.
32
In conclusion, the Subjective, Objective, and
Management parts of the LENT-SOMA scoring
system conﬁrm late toxic eﬀects on surrounding
normal tissue in all patients treated with a combined
treatment modality for locally advanced STS of the
extremity. Two-thirds of the patients have severe
Subjective or Objective damage, but half of all
patients do not require any Management for their
symptoms. To prevent long-term morbidity in the
future, eﬀorts should be made to reduce acute toxic
reactions after ILP, and a fasciotomy and a custom-
ized rehabilitation program are recommended. Fur-
thermore, anti-ﬁbrotic therapies might be considered.
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